Randomized trial: treatment of genitourinary syndrome of menopause using radiofrequency

References

• Phillips NA, Bachmann GA. The genitourinary syndrome of menopause. Menopause. 2021;28(5):579–588. PMID: 33534428. doi: 10.1097/GME.0000000000001728.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67(3):233–238. Epub 2010 Sep 9. PMID: 20828948. doi: 10.1016/j.maturitas.2010.08.001.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790–1799. Epub 2013 May 16. PMID: 23679050. doi: 10.1111/jsm.12190.
   PubMed Web of Science ®Google Scholar
• Mili N, Paschou SA, Armeni A, et al. Genitourinary syndrome of menopause: a systematic review on prevalence and treatment. Menopause. 2021;28(6):706–716. PMID: 33739315. doi: 10.1097/GME.0000000000001752.
   PubMed Web of Science ®Google Scholar
• The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. Menopause. 2020;27(9):976–992. PMID: 32852449. doi: 10.1097/GME.0000000000001609.
   PubMed Web of Science ®Google Scholar
• Rozenberg S, Vandromme J, Antoine C. Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol. 2013;9(4):216–227. doi: 10.1038/nrendo.2013.17.
   PubMed Web of Science ®Google Scholar
• Worsley R, Bell RJ, Gartoulla P, et al. Low use of effective and safe therapies for moderate to severe menopausal symptoms: a cross-sectional community study of Australian women. Menopause. 2016;23(1):11–17. PMID: 26240945. doi: 10.1097/GME.0000000000000495.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey. Climacteric. 2012;15(1):36–44. Epub 2011 Dec 14. PMID: 22168244. doi: 10.3109/13697137.2011.647840.
   PubMed Web of Science ®Google Scholar
• Antoine C, Vandromme J, Fastrez M, et al. A survey among breast cancer survivors: treatment of the climacteric after breast cancer. Climacteric. 2008;11(4):322–328. doi: 10.1080/13697130802244422.
   PubMed Web of Science ®Google Scholar
• Baumgart J, Nilsson K, Evers AS, et al. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause. 2013;20(2):162–168. doi: 10.1097/gme.0b013e31826560da.
   PubMed Web of Science ®Google Scholar
• Kendall A, Dowsett M, Folkerd E, et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17(4):584–587. doi: 10.1093/annonc/mdj127.
   PubMed Web of Science ®Google Scholar
• Melisko ME, Goldman ME, Hwang J, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for Early-Stage breast cancer: a randomized clinical trial. JAMA Oncol. 2017;3(3):313–319. doi: 10.1001/jamaoncol.2016.3904.
   PubMed Web of Science ®Google Scholar
• Donders GGG, Ruban K, Bellen G, et al. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother. 2019;20(7):821–835. Epub 2019 Mar 21. PMID: 30897020. doi: 10.1080/14656566.2019.1574752.
   PubMed Web of Science ®Google Scholar
• Salvatore S, Pitsouni E, Grigoriadis T, et al. CO2 laser and the genitourinary syndrome of menopause: a randomized sham-controlled trial. Climacteric. 2021;24(2):187–193. Epub 2020 Oct 22. PMID: 33089713. doi: 10.1080/13697137.2020.1829584.
   PubMed Web of Science ®Google Scholar
• Casiraghi A, Calligaro A, Zerbinati N, et al. Long-term clinical and histological safety and efficacy of the CO2 laser for treatment of genitourinary syndrome of menopause: an original study. Climacteric. 2023;26(6):605–612. Epub 2023 Aug 31. PMID: 37650754. doi: 10.1080/13697137.2023.2246886.
   PubMed Web of Science ®Google Scholar
• Li FG, Abbott JA. Vaginal laser therapy for GSM/VVA: where we stand now – a review by the EUGA working group on laser. Climacteric. 2023;26(6):638–638. Epub 2023 Dec 1. PMID: 37782251. doi: 10.1080/13697137.2023.2259791.
   PubMedGoogle Scholar
• Vicariotto F, DE Seta F, Faoro V, et al. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety. Minerva Ginecol. 2017;69(4):342–349. doi: 10.23736/S0026-4784.17.04072-2.
   PubMed Web of Science ®Google Scholar
• Fasola E, Bosoni D. Dynamic quadripolar radiofrequency: pilot study of a new High-Tech strategy for prevention and treatment of vulvar atrophy. Aesthet Surg J. 2019;39(5):544–552. Pages doi: 10.1093/asj/sjy180.
   PubMed Web of Science ®Google Scholar
• Mension E, Alonso I, Anglès-Acedo S, et al. Effect of fractional carbon dioxide vs sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause: the LIGHT randomized clinical trial. JAMA Netw Open. 2023;6(2):e2255697. Erratum in: JAMA Netw Open. 2023 Mar 1;6(3):e235334. PMID: 36763359; PMCID: PMC9918877. doi: 10.1001/jamanetworkopen.2022.55697.
   PubMed Web of Science ®Google Scholar
• Page AS, Verbakel JY, Verhaeghe J, et al. Laser versus sham for genitourinary syndrome of menopause: a randomised controlled trial. BJOG. 2023;130(3):312–319. Epub 2022 Nov 15. PMID: 36349391. doi: 10.1111/1471-0528.17335.
   PubMed Web of Science ®Google Scholar
• Hutchinson-Colas J, Segal S. Genitourinary syndrome of menopause and the use of laser therapy. Maturitas. 2015;82(4):342–345. Epub 2015 Aug 12. doi: 10.1016/j.maturitas.2015.08.001.
   PubMed Web of Science ®Google Scholar
• Bouchard C, Labrie F, Derogatis L, et al. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Horm Mol Biol Clin Investig. 2016;25(3):181–190. doi: 10.1515/hmbci-2015-0044.
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000;61(10):3090–3096. PMID: 10839558.
   PubMed Web of Science ®Google Scholar
• Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208. PMID: 10782451. doi: 10.1080/009262300278597.
   PubMed Web of Science ®Google Scholar
• Erekson EA, Yip SO, Wedderburn TS, et al. The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause. 2013;20(9):973–979. PMID: 23481118; PMCID: PMC3695224. doi: 10.1097/GME.0b013e318282600b.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016(8):CD001500. PMID: 27577677; PMCID: PMC7076628. doi: 10.1002/14651858.CD001500.pub3.
   PubMedGoogle Scholar
• Dos Santos CCM, Uggioni MLR, Colonetti T, et al. Hyaluronic acid in postmenopause vaginal atrophy: a systematic review. J Sex Med. 2021;18(1):156–166. PMID: 33293236. doi: 10.1016/j.jsxm.2020.10.016.
   PubMed Web of Science ®Google Scholar
• Hickey M, Baber R, Eden J, et al. Safety and effectiveness of a novel home-use therapeutic ultrasound device for the treatment of vaginal dryness in postmenopausal women: a pilot study. Menopause. 2023;30(4):383–392. PMID: 36749915. doi: 10.1097/GME.0000000000002157.
   PubMed Web of Science ®Google Scholar
• Sarmento ACA, Costa APF, Lírio J, et al. Efficacy of hormonal and nonhormonal approaches to vaginal atrophy and sexual dysfunctions in postmenopausal women: a systematic review. Rev Bras Ginecol Obstet. 2022;44(10):986–994. Epub 2022 Nov 29. PMID: 36446564; PMCID: PMC9708399. doi: 10.1055/s-0042-1756148.
   PubMedGoogle Scholar
• Statement from FDA Commissioner Scott Gottlieb, MD, on efforts to safeguard women’s health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for “vaginal rejuvenation.” 2018. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm615130.htm
   Google Scholar
• Garcia de Arriba S, Grüntkemeier L, Häuser M, et al. Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: Prospective, randomised study. PLoS One. 2022;17(5):e0266633. PMID: 35551533; PMCID: PMC9098008. doi: 10.1371/journal.pone.0266633.
   PubMed Web of Science ®Google Scholar